Sec Form 4 Filing - BIOASIA MANGEMENT LLC @ SOLENO THERAPEUTICS INC - 2019-05-17

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person BIOASIA MANGEMENT LLC 2. Issuer Name and Ticker or Trading Symbol SOLENO THERAPEUTICS INC [ SLNO] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 192 LYTTON AVENUE, 3. Date of Earliest Transaction (MM/DD/YY) 05/17/2019 (Street) PALO ALTO, CA94301 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 05/17/2019 S 1,492 D $ 1.98 ( 3 ) 9,856 I See Footnote ( 1 ) Common Stock 05/20/2019 S 9,856 D $ 1.92 ( 4 ) 0 I See Footnote ( 1 ) Common Stock 05/17/2019 S 10,434 D $ 1.98 ( 3 ) 68,942 I See Footnote ( 2 ) Common Stock 05/20/2019 S 68,942 D $ 1.92 ( 4 ) 0 I See Footnote ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securitie s Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other BIOASIA MANGEMENT LLC 192 LYTTON AVENUE PALO ALTO, CA94301 X BIOASIA INVESTMENTS IV LLC C/O VIVO CAPITAL LLC 192 LYTTON AVENUE PALO ALTO, CA94301 X Signatures /s/ Frank Kung as a managing member of BioAsia Management, LLC 05/21/2019 Signature of Reporting Person Date /s/ Frank Kung as a managing member of BioAsia Investments IV, LLC, 05/21/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The shares of common stock are held directly by Biotechnology Development Fund II, L.P. ("BDF II"). BioAsia Management, LLC is the sole general partner of BDF II, and may be deemed to beneficially own the shares of common stock owned by BDF II. BioAsia Management, LLC disclaims beneficial ownership of the shares of Soleno Therapeutics held by BDF II, except to the extent of its pecuniary interest therein. The voting members of BioAsia Management LLC are Frank Kung, Edgar Engleman and Anselm Leung, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares. ( 2 )The shares of common stock are held directly by Biotechnology Development Fund IV, L.P., Biotechnology Development Fund IV Affiliates, L.P., and BDF IV Annex Fund, L.P. (collectively, "Vivo Fund IV"). BioAsia Investments IV, LLC is the general partner of Vivo Fund IV and may be deemed to be beneficially own such shares. The voting members of BioAsia Investments IV, LLC are Frank Kung and Edgar Engleman, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares. ( 3 )The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.90 to $2.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. ( 4 )The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.89 to $2.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.